Socié G, Sélimi F, Sedel L, Frija J, Devergie A, Esperou Bourdeau H, Ribaud P, Gluckman E
Service de Greffe de Moëlle, Hôpital Saint Louis, Paris, France.
Br J Haematol. 1994 Mar;86(3):624-8. doi: 10.1111/j.1365-2141.1994.tb04795.x.
In the present study we describe the incidence, clinical course, and management of avascular necrosis of bone following allogeneic bone marrow transplantation, and identify risk factors related to its development. All patients developing avascular necrosis of bone after allogeneic bone marrow transplantation between January 1974 and September 1992 were included in the analysis and were studied using the Hôpital Saint Louis Bone Marrow Transplant Database and hospital records. 27/727 allogeneic transplant recipients developed avascular necrosis leading to an 8.1% incidence at 5 years, by product limit estimate, ranging from 5% to 11.2%. Symptoms developed 119-1747 d (median 398 d) after transplantation. In these 27 patients a total of 52 joints were affected (mean 1.92 per patient, range 1-7). The hip joint was most often affected (69% of patients). All patients had joint pain that led to diagnosis by means of standard radiographs with or without the help of technetium-99 scans and/or magnetic resonance imaging. All but three patients received steroid therapy for acute graft-versus-host disease. Among 10 factors tested, three were shown to be significantly linked to an increased risk for developing avascular necrosis by multivariate analysis: male gender (relative risk (RR) 4.72, P = 0.002), age older than 16 (RR = 3.87, P = 0.004), and acute graft-versus-host disease requiring steroid therapy (RR = 6.30, P = 0.0002). 10 patients (37%) required joint replacement within 19 months (range 2-42) following diagnosis of avascular necrosis. In conclusion, avascular necrosis of bone is a frequent late complication of allogeneic bone marrow transplantation causing significant morbidity and requiring replacement surgery in one-third of affected patients. In this 18-year single-centre survey, older age, male gender and steroid therapy given for acute graft-versus-host disease were shown to independently increase the risk of avascular necrosis of bone.
在本研究中,我们描述了异基因骨髓移植后骨缺血性坏死的发生率、临床病程及治疗方法,并确定了与其发生相关的危险因素。对1974年1月至1992年9月期间所有异基因骨髓移植后发生骨缺血性坏死的患者进行分析,利用圣路易医院骨髓移植数据库和医院记录展开研究。727例异基因移植受者中有27例发生骨缺血性坏死,根据乘积限估计法,5年时的发生率为8.1%,范围在5%至11.2%之间。症状出现在移植后119 - 1747天(中位时间398天)。这27例患者中,共有52个关节受累(平均每位患者1.92个,范围为1 - 7个)。髋关节最常受累(69%的患者)。所有患者均有关节疼痛,通过标准X线片诊断,部分患者借助锝 - 99扫描和/或磁共振成像。除3例患者外,所有患者均接受了针对急性移植物抗宿主病的类固醇治疗。在检测的10个因素中,多因素分析显示有3个因素与骨缺血性坏死发生风险增加显著相关:男性(相对风险(RR)4.72,P = 0.002)、年龄大于16岁(RR = 3.87,P = 0.004)以及需要类固醇治疗的急性移植物抗宿主病(RR = 6.30,P = 0.0002)。10例患者(37%)在骨缺血性坏死诊断后的19个月内(范围2 - 42个月)需要进行关节置换。总之,骨缺血性坏死是异基因骨髓移植常见的晚期并发症,会导致显著的发病率,三分之一的受累患者需要进行置换手术。在这项为期18年的单中心调查中,年龄较大、男性以及针对急性移植物抗宿主病进行的类固醇治疗被证明会独立增加骨缺血性坏死的风险。